¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-09-03

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-09-03
±³À°ÀÏÀÚ : 2021-09-03
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À° (½Ç½Ã°£ È­»ó±³À°)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : °­ÇØÁø
¿¬¶ôó : 02-735-2857  
À̸ÞÀÏ : ksmo3@ksmo.or.kr      
±³À°Á¾·ù : ³»°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°úÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í Àüµî·Ï : ȸ¿ø(±³¼ö,Àü¹®ÀÇ,ÀüÀÓÀÇ) -> 5¸¸¿ø ºñȸ¿ø -> 7¸¸¿ø/ ȸ¿ø(Àü°øÀÇ,°£È£»ç,¾à»ç,±ºÀÇ°ü) -> 3¸¸¿ø, ºñȸ¿ø ->5¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ09:00~09:40 Tumor heterogeneity and treatment resistance  Joan S BRUGGE(Harvard Medical School) 
È޽Ġ09-03 ½Ç½Ã°£¿Â¶óÀΠ09:40~10:00   () 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ10:00~10:22 Adjuvant treatment with IO : one size fits all?? : selection of patients who need adjuvant IO  Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ10:22~10:44 Conducting clinical trials of adjuvant treatment with targeted therapy  ¹Ú¿¬Èñ(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ10:44~11:06 Incorporation of Palliative Care in ASCO  Ishwaria Mohan Subbiah(The University of Texas MD Anderson Cancer Center) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ11:06~11:28 Introduction of Korean Academy of Supportive Care in Cancer  ±ÇÁ¤Çý(¼¼Á¾Ãæ³²´ëÇб³º´¿ø) 
Åä·Ð 09-03 ½Ç½Ã°£¿Â¶óÀΠ11:28~11:30 Q&A  -(-) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ11:30~12:10 Tecentriq + Avastin : Reigniting progress in the HCC treatment landscape  À¯Ã¢ÈÆ(¼­¿ï¾Æ»êº´¿ø) 
È޽Ġ09-03 ½Ç½Ã°£¿Â¶óÀΠ12:10~12:40   () 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ12:40~13:05 Emergence of immunotherapy in HCC: what  Ghassan ABOU-ALFA(MSKCC) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ13:05~13:30 Dawn of a new era for biliary tract cancer: targeted and immunotherapy  ¿Àµµ¿¬(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ13:30~13:55 Beyond PARPi and novel therapy in pancreatic cancer  Teresa MACARULLA(VHIO) 
Åä·Ð 09-03 ½Ç½Ã°£¿Â¶óÀΠ13:55~14:00 Q&A  -(-) 
È޽Ġ09-03 ½Ç½Ã°£¿Â¶óÀΠ14:00~14:20   () 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ14:20~14:42 Neoadjuvant chemotherapy followed by surgery in locally advanced pancreato-biliary cancer   ÀåÁø¿µ(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ14:42~15:04 Recent advances in neoadjuvant chemotherapy for locally advanced pancreato-biliary cancer  À¯Ã¢ÈÆ(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ15:04~15:26 Primary breast surgery for newly diagnosed stage IV breast cancer patients  Á¤¼Ò¿¬(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ15:26~15:48 How to manage stage IV breast cancer patients with oligometastasis  ±èÇÑÁ¶(¼øõÇâ´ëõ¾Èº´¿ø) 
Åä·Ð 09-03 ½Ç½Ã°£¿Â¶óÀΠ15:48~15:50 Q&A  Á¤¹Î±Ô(¿¬¼¼¾Ïº´¿ø) 
È޽Ġ09-03 ½Ç½Ã°£¿Â¶óÀΠ15:50~16:00   () 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ16:00~16:20 Bacterial infections and human cancer  Thomas F. MEYER(Max Planck Institute for Infection Biology) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ16:20~16:40 HBV Infection–Based HCC TME and immunotherapy  Valerie Chew Suk PENG(Translational Immunology Institute (TII)) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ16:40~17:00 Screening for early nasopharyngeal cancers by circulating Epstein-Barr virus DNA analysis  KC Allen CHAN(The Chinese University of Hong Kong) 
±³À°½Ã°£ 09-03 ½Ç½Ã°£¿Â¶óÀΠ17:00~17:40 Drug development in oncology: the revolution of the last 15 years  Jean-Charles SORIA(Amgen) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (2ÀÏÂ÷) : 2021-09-03""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2021³â Á¦16Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2021-09-03
´ÙÀ½±Û ´ëÇÑÇǺΰúÇÐȸ ´ë±¸°æºÏÁöºÎ Á¦ 251Â÷ ÇмúÁý´ãȸ : 2021-09-02
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20908 ¼­¿ï Á¦19Â÷ ´ëÇѸðÀ¯¼öÀ¯ÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-07-07 0 18 2024-05-28
20907 °æ±â Á¦2Â÷ ´ëÇѽŰæ¹æ»ç¼±¼ö¼úÇÐȸ Á¤±âÇмú´ëȸ : 2024-07-06 0 16 2024-05-28
20906 °æ±â Á¦ 5ȸ ¿À»ê½ÃÀÇ»çȸ Çмú´ëȸ : 2024-07-06 0 18 2024-05-28
20905 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦3ȸ ¾Æ»êµÎ°æºÎ Æ÷·³ : 2024-07-06 0 21 2024-05-28
20904 ¼­¿ï 2024³â Á¦2ȸ °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ¼øȯ±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 26 2024-05-28
20903 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day3) : 2024-07-06 0 20 2024-05-28
20902 ¼­¿ï ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ 2024³â ÇÏ°è NeurocrItical Care Essence (NICE) ¾ÆÄ«µ¥¹Ì : 2024-07-06 0 13 2024-05-28
20901 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø Á¦10ȸ ºÎ½Å¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 16 2024-05-28
20900 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 7 2024-05-28
20899 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 18 2024-05-28
20898 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 15 2024-05-28
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 10 2024-05-28
20896 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 14 2024-05-28
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 12 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 32 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷